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Gabapentin in the Treatment
of Bipolar Disorder
Wendi M. Waits and Donald P. Hall , MD

Abstract

Gabapentin, a relatively new anti-epileptic drug (liED), is emerging as a therapeutic option
JOr treatment refractory and rapid-cycling bipolar illnesses. Pharmacotherapy JOr bipolar disorders
traditionally involves oalproate, carbamazapine, or lithium, drugs which are associated with
numerous adverse effects. Conversely, gabapentin has an attractive pharmacokinetics profile and
relativelyje w side effects. There are no large randomizedcontrolled clinical trials to date examining
gabapentin's role in mood stabilization. However, informal reports have cited encouraging results in
up to 80% if patients and general tolerance to side ifJects. Thesefin dings make the new drug a
possible choicefor patients who haveJailed to respond to traditional agents or developed side effects
which interfere with medication compliance.

METHODOLOGY
A literatu re search of th e Med lin e and Silver Platt er dat ab ases was pe rform ed.
English la ngu age articles pu blish ed be twee n 1990- 1997 were reviewed . Keywords
" ga ba pe ntin," " bipola r," "e pile psy," a nd " psychia t ry" were used in va rious combinations. All articl es whi ch addressed t he use of ga ba pe n tin in human subj ects we re
conside re d . Review of citations in t hes e articles led to furth e r referen ces to th e
clinical use of ga ba pe n tin. All cita tions relat ed to th e use of ga ba pentin in th e
t re a t me n t of affec tive di sorders a re included in thi s review. Oth e r art icles which
add ress clinica lly usefu l ph arm acological issu es a re a lso includ ed.

CHEMISTRY
Ga ba pen tin (Ne uro n tin) is a cyclic gamm a-amino butyri c ac id (GABA) a nalog ue
whi ch may a lter GA BA tra nsmiss ion in t he centra l nervous syste m (I ). The mol ecul e
incorporat es a lipophilic cyclohe xa ne rin g into its s t ruc t u re, whi ch a llows gabapentin,
un like GA BA, to cross th e blood-brain barri er. P ha rmacokinetic a nd pharm acodynamic inve stigations have la rgely re lied on st udy of a nimals. The dr ug was initiall y
d evelop ed as a spas mo lyt ic bu t dem on strat ed e ffec tive a n tico nvu lsant properti es, and
thus e n te re d th e ph armaceutica l market as a n AED (2).
Early resea rch in to gabapentin 's m ech anism of ac tion fa iled to provid e strong
evide nce of GA BAergic ac tivity. It do es not a ppea r to sig n ificant ly bind to GABA-A,
GA BA-B, glu tama te, glycin e, or benzodiazapin e receptor s; it does not a ffec t volt ag e
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ga te d sod ium or calciu m channe ls, a nd it does not eleva te GABA conce n t ra tion in
nerve terminal s ( 1,3). How ever, ad m inis t ra tion of ga ba pe ntin has been ass ocia te d
with in cr eased GABA conce n t ra tion in th e subs tan tia nigra , a region rep eat ed ly
indi cat ed in th e activity ofGABAergi c anticonvulsants (4) .
G ab ap entin is tran sport ed ac ross e nte ric m embran es a nd most likely through
t he blood-brain ba rri er a nd into neuron s by a n L-amin o ac id carri er (2,5) . It s binding
site has been recen tly identifi ed as a subu nit of a calc ium cha nn el on neuronal ce ll
sur faces (3,6) . Gab apentin increases th e ra te of syn t hes is and accumu lat ion of GABA,
decr eases th e release of mon oamin es (do pa m ine, nor e pin eph ri ne, a nd serotonin),
a nd weakly inhibits GABA-transaminase, an e nzyme which degr ad es GABA into
ot he r a m ino ac ids (3,4).
PHARMACOKINETI CS

Gaba pe n tin is becomi ng popu la r a mo ng pracu t io n e rs du e to its favorabl e
ph a rm acokinetics profil e. It is effic ie nt ly a bsorbed in th e gu t following or a l ingestion.
Th e drug has a hal f-life of 5- 9 hours, rea ch es peak plasm a conce ntrat ion in 2-3 hours,
a nd ac hieves ste ady sta te in 1- 2 days. It is wat e r-soluble an d non-pr ot ei n-bound , bu t
is di stribut ed th rou gh out th e bod y (includ ing th e CNS) by means of protein transport. Gabap entin is not meta bolized , is comple tely elim inat ed by th e kid neys, a nd
does no t interact wit h hep at ic enzymes. T hese q ua liti es t heoreti ca lly elim ina te
pot e ntial int e racti on s wit h ot her m ed ica ti ons (2,5,7) .
CLINICAL USE

Co n trolled clinical t rials of ga ba pe nti n in t he t reat me nt of psychiatric dis orders
have not been pe rformed . Seve ra l anecdotal reports of use exist in th e medi ca l
lit erature (8- 12), incl udi ng a growing nu mb er of docum ents pertaining to ga ba pe ntin 's ro le in bipo la r illn ess. Howeve r, mos t dat a regarding t he drug's efficacy a nd
safety a ppear in rep ort s of ga ba pe n tin's use as a n an ticonvulsan t. T his informa tion
has se rved as a valuabl e guide to pr eliminary st ud ies in th e ment al health are na .
Th ree large ra nd omized cont rolled clin ica l t ria ls have eva luat ed th e efficacy and
safety of adj unc tive ga ba pe n tin th erapy in trea ting refractory e pile psy: th e UK
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G ab ap entin St udy G roup ( 1990), the US G ab ap e nt in St udy Group No.5 (1993), a nd
th e Int ernation al Gab apentin St udy Group (1994) . Dr ug dosages ranged from 600
mg/d to 1800 mg/d , with th e most effective dosin g regim en re ported to be 1800 mg/d.
Th e percent ages of patients in whom se izure fre quency decreased at lea st 50%
(res po nde rs) we re 25%, 26%, and 28%, resp ectively ( 19). Morris has since report ed a
re trosp ective a nalysis of 100 pati ents on ga ba pe n tin, 72 of whom experien ced a
greate r th an 50% reducti on in se izu re fre q ue ncy. Th e mean drug dos e in this pati ent
population was 210 7 mg/d ; 37 of th e 72 who resp onded (5 1%) were ta king 1800 mg/d
or less. The remaining patients took 1800-3600 rug/day (20) .
Data regarding th e rol e of ga ba pe ntin in th e t reat m e nt of bipolar disord ers is
pr eliminary, ye t e nco u raging . In on e retrosp ecti ve st udy of bip ola r pa tie n ts who had
fa iled to respond to tradition al mood stabilize rs or d evelop ed intolera ble sid e effects
from th es e agents , 92% responded positively to ga ba pe nt in (14) . All other publ ish ed
studies, consisting of op en trials whi ch have includ ed ga ba pe nt in bot h as monoth erapy and in addition to oth er psychotropic m edi cation s, have re ported effect ive
improvem ent in th e majority of pati ents (13,15 ,17 ,18) . Mo st pati ents have d isp layed
noticeable improvem ent in cycling activity with 200-3600 mg/d , th ou gh doses as low
as 33 mg /d a nd as high as 4900 mg/d ha ve been re por te d ( 13, 15). Ga ba pen tin may
also have antidepressant effec ts: pati ents on th e new AED have noted im prove me nt
in mood , m emory att ention , e ne rgy, slee p, and libido ( 10, 13, 17). Elevation in mood
whi ch accompanied th e transition fro m t radition al AE Ds to gabapentin , howeve r,
may have result ed from di scontinuati on of th e se dating side effects of th e tradi tional
agen ts . Further st udy is need ed to det ermine if ga ba pe nt in has inh e re nt antidepressa nt effec ts.

SAFETY

Gab apent in has proven its el f to be a relativel y sa fe drug. The most commonlye ncoun te re d side effec ts a re so m no le nce (24%), di zzin ess (20%), ataxia (17%), and
fatigu e (14%) (19). Less fr equent sid e effor ts include involunt ary twitches (1.3%),
rash (0.5%), leukopeni a (0.2%) , azo te m ia (0. 1%), t hrom bocyto pe nia (0. 1%), stutt erin g (I case), a nd weight ga in (19,21,22). The re have been several report ed cas es of
hypomania and/or in cr eased mood cycling ( 14, 15, 17,23) a nd th e re has be en on e cas e
of oculogyri c crisis whi ch was emerge n tly reversed wit h a ben zodi azep in e (22).
A th erap eutic range for ga ba pe ntin has ye t to be es ta blishe d . Peak steady-state
plasma levels of th e drug ave rage a bou t 4 mi crograms/ml (7). The re has bee n on e
report ed case of overdose, in whi ch a 16-year-old in gest ed 163 ca ps u les (49,900 mg)
without e me sis or return of pill frag me n ts on gas tr ic lavage. H er plasma gabapentin
level was 62 mi crogram s/ml at 8.5 hours afte r ingesti on. She was letha rgic, but was
easily aroused and a ble to co nve rse normall y; by 18 hours post -in gesti on, sh e was al ert
and without com pla in ts (24) . This case report is cons iste nt wit h a nimal toxicity test s,
in whi ch mi ce a nd rats experie nce d only a taxia a nd labored breat hing at maximum
dose of 2000 mg/k g IV a nd 8000 mg/k g PO. No ne of t he animals expired (24).
Gabapentin has seve ral prop erties whi ch sign ifican tly reduce its pot ential for
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int eraction with oth er drugs. It is non-prot ein-bound , it does not affect hep atic
e nzym e ac tivity, and it has no met ab olit es (2) . Alt ho ug h clinica l trials have not
rep ort ed a ny cases of drug-drug inte racti on s invo lving gabape ntin (20), a nd so me
so urces have suggeste d th at suc h int e racti ons are impossibl e (25,26), several rep ort s
have suggested th at th e dru g m ay occas ionally affect or be influe nced by ot he r
medi cation s.
In on e s tudy, a th erap eutic dos e of a lu m in um a nd magn esium hydroxide
(M aa lox) , adm inis te re d concom ita ntly with or shortly afte r 400 mg of ga bapentin,
reduced th e bioavail ability of th e latt er by 20% (2 7). C ime tidin e has report edl y
decr eased t he renal clearance of ga ba pe ntin by a cli nica lly significant a moun t (7).
The re ha s been one case rep ort of ga ba pe n tin int e racting with phenytoin . A patient
wit h a lon g hist ory of com plex partial a nd seconda rily gen eralized seizures, who was
on three AED 's, began taking ga bape nt in. Hi s plasm a phenytoin con centration
subseque ntly incr eased from 42 to 177 mi cro gr am slL a nd return ed to baseli ne upon
removal of th e new drug (28). Finally, ga ba pe ntin has been assessed as unlikely to
ca use contracep tive failure wh en tak en with oral co ntrace ptives (7) .
Th ere a re few rep orts of pr egn ant wom en ta king gabape ntin . No teratogeni c
effects have bee n not ed in a ny of t he 10 reports on file (29). The drug is, however,
fe totoxic in rode n ts, associa te d with del ayed oss ification, hydrouret er, and hydron ephrosis a t doses up to four tim es great e r t ha n rela tive standard human dosages (i.e.
3600 m g/d ). There was a lso an incr eased incid en ce of pa ncr eatic acinar cell tumors in
mal e rats a t high do ses, though th ei r life spa n was not a ffec ted by th e neoplasms (30).
Potenti al uses of ga ba pe ntin in th e pedi at ric affect ive d isorders popu lations have ye t
to be dete rmined.
DOSI G

Form al dosin g guide lines a re not ava ila ble for th e use of gabape n tin in bipol a r
d isord e rs. Maint en an ce doses for se izure con trol ra nge fro m 900-2400 mg/d (2,6,19,26)
and pr eli mi na ry t rial s of ga bapen tin for mood stabilization seem to sugge st a sim ila r
dos e range. The drug's re la tively sho rt hal f-life ne cessit at es T ID ad m inist ra tion.
Gabapentin treat ment for refract ory seizu res is gen era lly init iat ed with 300 mg once
on t he first day, 300 mg twice on t he second day and 300 mg three tim es on th e third
day, wit h subse q ue nt incr eases in TID dose as req uired for symptom con t rol (2,19).
O f some clini cal significa nce is t he fact th at all stu di es to da te exa mining
ga ba pe nt in in th e t reatm ent of bip ola r illness have inclu d ed pati ents who responded
to a dose less t han 900 mg/d ( 13- 18). In on e study of 28 pati ent s, th e mean
gabapen tin dos e was 539 mg/d ( 15). H ence, increasing dos es by 200 mg inst ead of300
mg may be more appropria te for mood stabi lization.
DISCUSSIO N

All of th e m edi cation s presently used to treat bipolar d isor de r have significa nt
side effects which impact both qu ality of life and th erapeutic com plia nce. Unfortu-
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nat ely, in this patient population , di ssatisfaction wit h trea t m e n t regimen s has th e
pot enti al to sign ifica n tly wor sen th e patient 's clin ica l course by magnifying feelings of
hop elessn ess in a d epressed pa tie nt. Gab ape ntin hold s promise as an adj unc tive for m
of treatment whi ch has few inh erent di sadvant ages and littl e cha nce of interacting
with ot he r drugs. It s favo ra ble ph armacok in etics profi le is unique a mong mood
stabilize rs . Th e drug has relat ively few side effects, most of which are beni gn in
natu re. It s possibl e a ntide pressant effec ts a nd hypoma nic sid e effe cts need fu rth er
st udy. It has thus fa r demon strat ed low toxi cit y a t t he ra pe u tic dos es and in ove rdo se.
Gabape nt in has displ ayed clinical efficacy in up to 80% of bipolar pati en ts in
preliminary clinical t rial s, a nd is presently undergoin g investigation as a possibl e
age n t in th e treatment of mi gr ain e headach es, chronic pain, a nd behavioral di sor de rs. Few reports of ga ba pe ntin's use in human pr egn ancy ex ist, and animal studies
ha ve been somewhat dis couragin g.
Current psychi at ric use of ga ba pe ntin is restrict ed to pa tie n ts who have fai led to
respond to traditional age nts or d eveloped intol erabl e side effects from t he m. Th e
upper limit of th e drug' s th erapeutic range mu st be established. P roble ms with
m edi cation com plia nce m ay be improved throu gh th e d evelopm e n t of an exte nde dre lease or dep ot form of ga ba pe ntin. A large, multi cen ter, randomized, controlled
clinica l trial has ye t to be perform ed.
CONCLUS IONS

Gab apen tin is a GABA a na log ue a nd new AE D whi ch has th e unique a bility to
cross t he blood-brain ba r rier. It appears to influence ne u ro psychologica l ac tivity by
ac ting on calciu m chan nels in th e CNS. It has a favorabl e ph armacok in etics pro file
an d is provin g to be re la tively sa fe in clinica l practice. The drug has displayed both
mood-stabilizing a nd poss ible an ti-de pressant act ivity in pr eliminary tri al s, and is
associated with a relatively beni gn side profile . Fu rt he r study of thi s new AED is
clea rly need ed.
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